JP2021518392A5 - - Google Patents

Info

Publication number
JP2021518392A5
JP2021518392A5 JP2020550648A JP2020550648A JP2021518392A5 JP 2021518392 A5 JP2021518392 A5 JP 2021518392A5 JP 2020550648 A JP2020550648 A JP 2020550648A JP 2020550648 A JP2020550648 A JP 2020550648A JP 2021518392 A5 JP2021518392 A5 JP 2021518392A5
Authority
JP
Japan
Prior art keywords
disease
composition according
auc last
disorders
subject
Prior art date
Application number
JP2020550648A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2019183333A5 (https=
JP2021518392A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2019/023338 external-priority patent/WO2019183333A1/en
Publication of JP2021518392A publication Critical patent/JP2021518392A/ja
Publication of JP2021518392A5 publication Critical patent/JP2021518392A5/ja
Publication of JPWO2019183333A5 publication Critical patent/JPWO2019183333A5/ja
Pending legal-status Critical Current

Links

JP2020550648A 2018-03-22 2019-03-21 二官能性血液脳治療 Pending JP2021518392A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862646845P 2018-03-22 2018-03-22
US62/646,845 2018-03-22
PCT/US2019/023338 WO2019183333A1 (en) 2018-03-22 2019-03-21 Bifunctional blood brain therapies

Publications (3)

Publication Number Publication Date
JP2021518392A JP2021518392A (ja) 2021-08-02
JP2021518392A5 true JP2021518392A5 (https=) 2022-03-28
JPWO2019183333A5 JPWO2019183333A5 (https=) 2022-03-28

Family

ID=67986347

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020550648A Pending JP2021518392A (ja) 2018-03-22 2019-03-21 二官能性血液脳治療

Country Status (9)

Country Link
US (1) US20210046149A1 (https=)
EP (1) EP3818077A4 (https=)
JP (1) JP2021518392A (https=)
KR (1) KR20210004995A (https=)
CN (1) CN112292393A (https=)
AU (1) AU2019240218A1 (https=)
CA (1) CA3094179A1 (https=)
IL (1) IL277395A (https=)
WO (1) WO2019183333A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102905380B1 (ko) 2019-07-26 2025-12-30 뒤센펠드 게엠베하 리튬 배터리를 재활용하는 방법
US20210355468A1 (en) * 2020-05-18 2021-11-18 Bioasis Technologies, Inc. Compositions and methods for treating lewy body dementia

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2582869T3 (es) * 2011-07-05 2016-09-15 Bioasis Technologies Inc Conjugados de P97-anticuerpo
JP6586412B2 (ja) * 2013-03-13 2019-10-02 バイオアシス テクノロジーズ インコーポレイテッド ｐ９７のフラグメントおよびその使用

Similar Documents

Publication Publication Date Title
JP6403062B2 (ja) 組織修復活性組成物及びその利用
JP2013533858A5 (https=)
JP2019519528A5 (https=)
EP0585705A1 (en) Use of anti-TNF to treat bacterial meningitis
CA2730789A1 (en) Treatment of inflammatory bowel diseases with mammal beta defensins
JP2021514003A5 (https=)
JP2021075550A (ja) グルカゴン類似ペプチド−１受容体亢進剤を含む筋減少症治療用薬学組成物
JP2020517627A5 (https=)
JP2025122021A5 (https=)
JP2021518392A5 (https=)
JP2007500741A (ja) 一時的処置のための短い半減期を有するｃ１インヒビター
US8956605B2 (en) Prevention and/or treatment of multiple organ dysfunction syndrome with interleukin-22
US7947283B2 (en) Compositions and methods for treating psoriasis by Ganoderma lucidum (Reishi) polysaccharides
Lam et al. Targeting mesenchymal stem cell therapy for severe pneumonia patients
CN108939074A (zh) 治疗再生障碍性贫血的方法和药物组合物
JP2015524431A5 (ja) 視神経損傷、眼虚血または眼の再灌流傷害を治療または予防する医薬
JPWO2019183333A5 (https=)
KR20220024463A (ko) 시뉴클레인병증에 대한 치료
CN115279344A (zh) 盐酸米托蒽醌脂质体的用途
WO2025080877A3 (en) Therapeutic peptides
JPWO2020055812A5 (https=)
JPWO2021148411A5 (https=)
JP2020524132A5 (https=)
JP2021533113A5 (https=)
JP7792727B2 (ja) アミロイド前駆体タンパク質に対する阻害活性を有するペプチドおよびその用途